Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cardiovascular Risks with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors and Monoclonal Antibody Therapy.

Current oncology reports - 1 Apr 2022

Chitturi Kalyan R, Burns Ethan A, Muhsen Ibrahim N, Anand Kartik, Trachtenberg Barry H

Abstract excerpt

PURPOSE OF REVIEW: Tyrosine kinase inhibitors (TKI) and monoclonal antibodies (mAbs) that target the epidermal growth factor receptor (EGFR) have changed the therapeutic landscape across a range of solid malignancies. However, there is little data regarding the cardiovascular (CV) impact of these agents. The purpose of this review is to discuss reported CV effects, pathophysiology, pre-treatment screening,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cardiovascular Diseases

Share to ErbB Receptors

Share to Heart Disease Risk Factors

Share to Lung Neoplasms

Share to Neoplasms

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 35192115
DOI: 10.1007/s11912-022-01215-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cardiovascular Risks with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors and Monoclonal Antibody Therapy.PMID 35192115Read ↗

Cardiotoxicity Associated with Targeted Therapies in Lung Cancer: A Retrospective Cohort Study of 2,427 Patients with FAERS Pharmacovigilance ValidationSemantic proximity Read ↗

Research Progress on the Cardiotoxicity of EGFR-TKIs in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Pulmonary Embolism And Bradycardia in a NSCLC Patient Treated With Crizotinib For a Rare Mutation: A Case ReportSemantic proximity Read ↗

Cardiovascular events in EGFR-mutation non-small-cell lung cancer patients on osimertinib.Semantic proximity Read ↗

Pulmonary embolism and bradycardia in a NSCLC patient treated with crizotinib for a rare mutation.Semantic proximity Read ↗

Cardiac Effects of BRAF and MEK Inhibitors: Mechanisms and Clinical Management.Semantic proximity Read ↗

Diagnostic and Therapeutic Intervention for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors-associated Cardiotoxicity in Non-small-cell Lung Cancer: A Case StudySemantic proximity Read ↗

Possible heart failure caused by osimertinib in a lung cancer patient.Semantic proximity Read ↗

Cancer Therapeutics-Related Cardiac Dysfunction - Insights From Bench and Bedside of Onco-Cardiology.Semantic proximity Read ↗

Cardiovascular adverse events associated with epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer: systematic review and network meta-analysis.Semantic proximity Read ↗

Osimertinib- Cardiac Dysfunction with Prolonged QTc Interval: Case ReportSemantic proximity Read ↗

Prevalence and Effects of Late Cardiotoxicity induced by Anthracyclines and/or Anti- HER2 Antibodies in Patients with Breast Cancer: a real world studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.